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Background: Histone acetyltransferase (HAT) inhibitors can inhibit proliferation and induce apoptosis in cancer cell
lines. The novel cell-permeable p300/CREB-binding protein (CBP)-selective HAT inhibitor HATi II can reduce histone
H3 acetylation and induce chromatin condensation in HeLa cells. Here, we examined the effects and mechanism of
action of HATi II in glioma cell lines.
Methods: Cell viability was assessed using the CCK-8 assay. Cell cycle analysis was performed using flow cytometry.
Apoptosis was evaluated using Annexin V staining and flow cytometry, Hoechst 33342 staining and the TUNEL
assay. Expression and cleavage of caspase-3, caspase-9 and poly ADP-ribose polymerase (PARP) were assessed by
Western blotting. Statistical analysis was performed using two-tailed Student’s t-tests. The gene expression profiles
of U251 glioma cells treated with HATi II or DMSO were analyzed using the Arraystar Human 8 x 60 K LncRNA/
mRNA expression array; data was analyzed using MEV (Multi Experiment View) cluster software. Datasets representing
genes with altered expression profiles (≥2-fold) derived from the cluster analyses were subjected to gene ontology
and pathway analysis.
Results: HATi II inhibited the proliferation of U251, U87, HS683 and SHG44 cells in a dose-dependent manner. HATi II
induced cell cycle arrest at the G2/M phase, and induced significant levels of apoptosis, apoptotic body formation and
DNA fragmentation in HATi II-treated U251 and SHG44 cells. HATi II induced cleavage of caspase-3, caspase-9 and PARP
in U251 and SHG44 cells. In HATi II-treated U251 cells, 965 genes were upregulated, 984 genes were downregulated
and 3492/33327 lncRNAs were differentially expressed. GO analysis showed the differentially expressed genes with
known functions are involved in a variety of processes; alcoholism, p53 signaling pathway, cytokine-cytokine receptor
interaction and transcriptional mis-regulation in cancer were the four most significant pathways. Upregulation of p53
signaling pathway-related genes in HATi II-treated cells was confirmed by quantitative RT-PCR and Western blotting.
Conclusions: HATi II inhibits proliferation and induces apoptosis via the caspase-dependent pathway in human glioma
cell lines, possibly by activating the p53 signaling pathway. HATi II deserves further investigation as a novel treatment
for glioma.
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Gliomas are the most common type of primary brain
tumor in adults and second most common childhood
malignancy after leukemia [1,2]. The annual incidence of
glioma is approximately 3–8 per 10 million [3]. According
to the histopathological and clinical criteria established by
the World Health Organization (WHO), gliomas can be
grouped into four grades I–IV [4], and there are three
principal types of glioma: astrocytomas, oligodendrogli-
omas and oligoastrocytomas. Despite recent advances in
surgical resection, chemotherapy and radiotherapy, the
prognosis of patients with glioma continues to be very
poor; the five-year overall survival rate for glioma is less
than 10% [5] and is the third lowest of all cancers after
pancreatic and lung cancer [6-8].
Current standard therapies for newly-diagnosed glioma
include surgical resection followed by adjuvant radiother-
apy and/or chemotherapy [9]. Nevertheless, surgical resec-
tion is often limited by a lack of a clear primary tumor
margin and by the location of the tumor close to vital ana-
tomical structures. Moreover, the effectiveness of radio-
therapy and chemotherapy is suboptimal in many cases,
largely due to the rapid development of tumor cell resist-
ance to radiation and chemotherapeutic drugs. In addition,
the blood-brain barrier and side-effects limit the effective-
ness of chemotherapy drugs. Clinicians are eager to find
novel, more specific therapeutic options with fewer side-
effects for glioma; small-molecule inhibitors of molecular
targets may be promising candidate drugs.
Recent data has strongly indicated that alterations at
the histone level may play a role in glioma tumorigenesis.
Histone acetylation is one of the most well-characterized
epigenetic modifications and is controlled by histone ace-
tyltransferases (HATs) and histone deacetylases (HDACs)
[10]. HATs play a central role in the modification of chro-
matin to create a favorable environment for a number of
important cellular processes [11]. Acetylation neutralizes
the positive charge on lysine residues and thereby weakens
the bond between DNA and histone tails. Thus, histone
acetylation is linked to transcriptional activation, whereas
deacetylation is generally associated with transcriptional
repression. Deletions or inactivating mutations in multiple
genes encoding HATs have been associated with oncogen-
esis and tumor progression; these mutations alter the
transcription of genes that regulate key functions such as
proliferation, cell cycle progression and apoptosis [12,13].
Numerous genetic studies have also indicated that HATs
are important factors linked to a variety diseases, includ-
ing cancer [14,15].
Enzymes that catalyze the reversible post-translational
modification of histones on lysine residues by acetylation
and methylation have received attention as potential drug
targets in cancer and other diseases. A recent study found
that a variety of small-molecule inhibitors which targetHATs could affect cell proliferation and induce tumor cell
growth arrest, apoptosis and differentiation in prostate
cancer and neuroblastoma cell lines [16-18]. The effects of
HATs on cellular physiology and disease could potentially
be ameliorated via the use of specific pharmacological
inhibitors.
Very few specific HAT inhibitors have been identified;
however, several compounds with HAT-inhibitory activity
were recently identified. Interestingly, some of these com-
pounds have been shown to inhibit the growth of cancer
cells [19]. Anacardic acid, isolated from cashew nut shell
liquid, was identified as a potent non-competitive inhibi-
tor of both p300 and p300/CBP-associated factor (PCAF)
HAT activity in vitro [20]. Quinoline was reported to pro-
mote tumor cell apoptosis in human leukemia cell lines
by inhibiting p300 HAT activity [21]. Another p300/
CBP HAT inhibitor compound, C646, could inhibit the
growth of both human melanoma and non-small-cell-lung
(NSCL) cancer cell lines [22], and also could inhibit the
growth of primary blasts isolated from patients with t
(8;21)-positive acute myelocytic leukemia (AML) as well
as Kasumi-1 cells [23].
Histone acetyltransferase inhibitor II (HATi II) is a
novel cell-permeable bis-arylidene cyclohexanone com-
pound that acts as a p300/CBP-selective HAT inhibitor,
which can reduce histone H3 acetylation and induce
chromatin condensation in HeLa cells. The p300 protein
is a transcriptional co-activator with intrinsic HAT activity
that plays a crucial role in cell cycle progression, differen-
tiation and apoptosis. Inhibition of p300 suppresses the
cellular growth of melanoma cells [24] and induces apop-
tosis in prostate cancer cells [25]. P300 activity is also
required for the G1/S transition in cancer cells [26,27].
Despite the fact that the anti-tumor effects of p300 inhibi-
tors have been reported in other cancers, the effect of
inhibiting p300 has not been extensively investigated
in glioma cells. In the present study, we examined the
molecular function of HATi II in glioma cell lines, and
observed that HATi II can inhibit proliferation and induce
cellular apoptosis via the caspase-dependent apoptotic
pathway. In addition, microarray analysis and quantitative
real-time PCR indicated that HATi II activates the p53
signaling pathway in glioma cells. These results suggest




HATi II was purchased from Calbiochem (Billerica, MA,
USA) and dissolved in DMSO (Sigma-Aldrich, St. Louis,
MO, USA). The Cell Counting Kit-8 was obtained from
Dojindo Laboratories (Kumamoto, Japan); 4,6-diamidino-
2-phenylindole (DAPI) and Hoechst 33342 were purchased
from Sigma-Aldrich. Mouse monoclonal antibody against
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caspase-9, PARP, PTEN and CDK1 were purchased from
Cell Signaling Technology (Beverly, MA, USA); Reprimo,
RRM2, CCNE2 and SFN from Boster (Wuhan, China); and
p53 and p21 from Beyotime (Jiangsu, China). Anti-mouse
and anti-rabbit peroxidase conjugated secondary anti-
bodies were purchased from Pierce (Madison, WI, USA).
Cell culture
The glioma cell lines U251, U87, HS683 and SHG44
were obtained from the Cell Bank of the Chinese Academy
of Sciences (Shanghai, China). The cells were maintained
in DMEM (Invitrogen Life Technologies, Paisley, UK) con-
taining 10% fetal bovine serum (FBS; Hyclone, UT, USA)
at 37°C in 5% CO2. The cells were confirmed to be free
from mycoplasma every three months using a commercially
available kit (Invitrogen, Shanghai, China). All of the resear-
chers who contributed to this study received standard cell
culture training to prevent cell cross-contamination. The
study was approved by the Ethics Committee of Children's
Hospital of Soochow University.
Cell proliferation and viability assays
Glioma cells (2 × 104) were seeded in 96-well plates,
cultured overnight, and then incubated with DMSO or
varying concentrations of HATi II (2.5, 5, 7.5, 10, 12.5, 15,
17.5, 20 or 25 μM) for 48 h; the same volume of DMSO
was added to the vehicle-treated wells as the drug-treated
wells, and each drug concentration was tested in three
replicate wells. Then, 10 μL CCK8 solution (DOJINDO,
Shanghai) was added to each well, incubated at 37°C for
4 h and the optical density (OD) values were measured at
450 nm using a scanning multi-well spectrophotometer.
The survival rate of the treated cells was calculated rela-
tive to the control group. Cell proliferation was calculated
as a percentage of the DMSO-treated control wells; IC50
values were derived after plotting the proliferation values
on a logarithmic curve.
Western blot analysis
Glioma cells were harvested, washed and lysed using 1x
RIPA buffer. Protein concentrations were determined
using the BCA protein assay kit. Equal amounts of
protein from the cell lysates were separated on 10% SDS
polyacrylamide gels and transferred onto polyvinylidene
fluoride membranes. Membranes were blocked with 5%
non-fat milk in TBST and incubated with primary anti-
bodies against caspase 3, caspase 9, PARP, PTEN, CDK1,
Reprimo, RRM2, CCNE2 and SFN at 4°C overnight. Then,
the membranes were washed and incubated with second-
ary antibodies against rabbit or mouse IgG conjugated
to horseradish peroxidase (Cell Signaling) for 1 h, then
washed and the bands were visualized using chemilumin-
escence (ECL, Amersham-Pharmacia, Uppsala, Sweden);β-actin was used as an internal loading control. The
expression of the target proteins relative to β-actin was
used as a semi-quantitative comparison between different
groups.Cell cycle assays
Cells were seeded in 6-well plates (1 × 106 cells/well).
HATi II stock solution (10 mM in anhydrous DMSO)
was directly added to the culture media to achieve the
desired concentrations; the volume of DMSO was kept
constant at 0.1%. After treatment with HATi II or DMSO
for 24 or 48 h, the cells were harvested and subjected to
the following assays. For the cell cycle assay, the cells were
washed twice with ice cold PBS, fixed in 70% ethanol at 4°C
overnight, incubated with 10 mg/mL RNase A (Sigma-
Aldrich) at 37°C for 30 min, and then incubated with
50 mg/mL propidium iodide (Sigma-Aldrich). Cell cycle
distribution was assessed by flow cytometry (FC500,
Beckman Coulter, FL, USA).Cell apoptosis assays
Apoptosis assays were conducted using the BD Annexin
V Staining Kit (BD Biosciences, Franklin Lakes, USA) ac-
cording to the manufacturer’s instructions. Briefly, the
cells were washed twice with cold PBS, resuspended in 1×
Binding Buffer at a concentration of ~1 × 106 cells/ml,
100 μl of the cell suspension (~1 × 105 cells) was trans-
ferred to a 5 ml culture tube, 5 μl Annexin V and PI were
added, the cells were gently mixed, incubated for 15 min
in the dark at RT, 400 μl of 1× Binding Buffer was added
to each tube, and the cells were immediately analyzed by
flow cytometry (within 1 h).Hoechst 33342 staining analysis
Cells were seeded into 6-well plates, and then treated
with HATi II and cultured at 37°C for different periods
of time, stained with 0.1 μg/ml Hoechst 33342 (Sigma)
for 5 min, then observed by fluorescence microscopy using
appropriate filters for blue fluorescence.TUNEL assay
DNA double-strand breaks occur late in the apoptotic
pathway and were assessed using the TUNEL Apoptosis
Detection Kit (Cat: KGA704; Kengent, Nanjing, China).
Firstly, the cells were seeded on coverslips, treated with
10 μmol/L HATi II for 48 h, washed, fixed and stained
as per the manufacturer’s instructions, and the cell nuclei
were stained with 1 μg/mL 4’,6-diamidino-2-phenylindole
(DAPI). Apoptotic cells were observed by laser scanning
confocal microscopy (OLYMPUS IX71) at an excitation
wavelength of 515-565 nm.
Figure 1 (See legend on next page.)
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Figure 1 Growth inhibitory effects of HATi II in glioma cell lines. (A-D) Cell viability assay. Glioma cells cultured in 96-well plates were treated
with different concentrations of HATi II or DMSO for 48 h, and cell viability was determined using the CCK-8 assay. Cell proliferation was calculated as a
percentage of the DMSO-treated control cells; IC50 values were derived by plotting the proliferation values on a logarithmic curve. The experiments
were repeated three times. (E) Phase-contrast microscopy of U251, HS683, U87 and SHG44 cells treated with HATi II for 24 or 48 h (×100).
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hybridization
Total RNA was extracted from the cells using the single-
step TRIzol RNA extraction kit (Invitrogen, CA, USA)
according to the manufacturer’s instructions, concen-
trated by isopropanol precipitation and column-purified
using the Qiagen RNeasy Mini Kit (Cat No. 74104). The
integrity and concentration of the RNA samples were
assessed prior to labeling; RNA was quantified and assessed
using a NanoDrop ND-1000 (Thermo Scientific), RNA
integrity was assessed using denaturing agarose gel
electrophoresis. The Quick Amp Labeling Kit (Agilent
Technologies) was used for sample labeling and hybri-
dization to Arraystar_Human_LncRNA_8 × 60 k v3.01Figure 2 HATi II induces apoptosis in glioma cell lines. (A-C) U251 cells
apoptosis was determined by Annexin V-FITC/PI dual labeling and flow cytom
quantified (B, E); *p < 0.05 or **p < 0.01 compared with DMSO-treated contro
II for 24 or 48 h; DNA fragmentation was observed after 24 h and increased inmicroarrays was performed in Agilent Sure Hyb Hybri-
dization Chambers.
Data collection, normalization and analysis
After washing, the hybridized microarrays were scanned
using an Agilent DNA Microarray Scanner and data
was extracted using Agilent Feature Extraction software.
Quantile normalization and subsequent data processing
were performed using the GeneSpring GX v12.0 software
package (Agilent Technologies). After quantile normali-
zation of the raw data, mRNAs that had ‘Present’ or
‘Marginal’ flags in at least one out of two samples were
selected for differentially expressed mRNA screening. To
identify differentially expressed mRNAs, we performedor (D-F) SHG44 cells were treated with HATi II for 24 or 48 h and
etry (A, D), and the numbers of Annexin V (+) and PI (-)% cells were
l cells. (C, F) Cell cycle analysis of U251 and SHG44 cells treated with HATi
a time-dependent manner. These analyses were repeated three times.
Figure 3 (See legend on next page.)
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Figure 3 HATi II induces apoptosis, DNA fragmentation and activation of caspase-3 in glioma cell lines. (A, B) The morphologic changes
in U251 (A) and SHG44 cells (B) treated with HATi II were evaluated using Hoechst 33342 staining and fluorescence microscopy. (C, D) Apoptosis
was assessed by terminal deoxynucleotidyl transferase mediated dUTP nick end-labeling (TUNEL) analysis in U251 (C) and SHG44 cells (D) treated
with HATi II. Apoptotic cells (green) were detected by laser scanning confocal microscopy at an excitation of 515-565 nm, while the cell nuclei
were stained with DAPI. The two images have been superimposed to show the apoptotic cells (green) and their position. (E and F) Western-blot
analysis of the activation of caspase-3, caspase-9 and PARP in U251 (E) and SHG44 cells (F) treated with HATi II for 48 h.
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threshold fold change of ≥ 2.0. Further data analysis
was performed using Agilent GeneSpring GX v12.0 soft-
ware; this analysis was performed by KangChen Biotech,
Shanghai, PR China.
Gene ontology analysis and pathway analysis
Gene ontology (GO) analysis is a functional analysis
that associates differentially expressed mRNAs with GO
categories. The GO categories were derived from Gene
Ontology (www.geneontology.org), which comprises three
structured networks of defined terms that describe gene
product attributes. The ontology covers three domains:
biological process, cellular component and molecular
function. Fisher’s exact test was used to determine
whether the overlap between the differentially expressed
(DE) list and the GO annotation list was greater than that
expected by chance. The P-value denotes the significance
of the GO term enrichment in the DE genes after account-
ing for the false discovery rate. The lower the P-value,
the more significant the GO term (a P-value ≤ 0.05 is
recommended).
Pathway analysis is a functional analysis that maps genes
to KEGG (Kyoto Encyclopedia of Genes and Genomes)
pathways (http://www.genome.jp/kegg/). The P-value
(EASE-score, Fisher’s exact test P value, or hypergeometric
P-value) denotes the significance of the pathway correlated
to the conditions. The lower the P-value, the more signi-
ficant the correlation (the recommended P-value cut-off
is 0.05).
Real-time PCR verification of differentially expressed target
genes
Total cellular RNA was isolated using TRIzol reagent
(Invitrogen, CA, USA ) according to the manufacturer’s
protocol and 1 μg of total RNA was reverse transcribed
to cDNA using the ReverTra Ace qPCR RT Kit (Toyobo,
Osaka, Japan) following the manufacturer’s instructions.
Real-time PCR array analysis was performed in a total
volume of 20 μl, including 2 μl of cDNA, primers (0.2 mM
each) and 10 μl of SYBR Green mix (Roche). Reactions
were run on an Light cycler 480 (Roche) using uni-
versal thermal cycling parameters (95°C for 5 min,
45 cycles of 10 sec at 95°C, 20 sec at 60°C and 15 sec
at 72°C; melting curve: 10 sec at 95°C, 60 sec at 60°C and
then continued melting). Results were obtained using thesequence detection software of the Light cycler 480 and
analyzed using Microsoft Excel. The sequences of the
primers for the seven target genes and the internal control
gene (GAPDH) are listed in Additional file 1: Table S1.
Statistical analysis
The mean ± SD values presented in the figures were
calculated from three or more independent experiments.
Comparisons between groups were evaluated using two-
tailed Student’s t-tests; p < 0.05 was considered statistically
significant.
Results
HATi II inhibits the proliferation of glioma cells
U251, U87, SHG44 and HS683 cells were treated with
different concentrations of HATi II (0, 2.5, 5, 7.5, 10,
12.5, 15, 20 or 25 μmol/L) for 48 h, then cell prolifera-
tion was assessed using the CCK-8 kit. HATi II inhibited
proliferation in a dose-dependent manner in all four
glioma cell lines; DMSO (≤0.1%) had negligible influ-
ence on cell proliferation. The IC50 values for HATi
II at 48 h in U251, U87 and HS683 cells were approxi-
mately 12.17 ± 0.7489 μmol/L, 9.513 ± 0.8632 μmol/L and
9.558 ± 1.081 μmol/L; SHG44 cells were more sensitive to
HATi II than the other three cell lines with an IC50 of
5.9688 ± 0.5351 μmol/L (Figure 1A-1D).
Under the phase-contrast microscope, we observed
that treatment with HATi II markedly decreased the num-
bers of U251, HS683, U87 and SHG44 cells, and a large
proportion of the remaining cells became rounded and
smaller in size indicating that the cells were undergoing
apoptosis (Figure 1E).
HATi II induces apoptosis in U251 and SHG44 cells
To confirm whether HATi II induces apoptosis in glioma
cells, we subjected HATi II-treated U251 cells to the
Annexin V assay. Flow cytometry demonstrated that treat-
ment with 10 or 20 μM HATi II for 24 or 48 h signifi-
cantly increased the numbers of apoptotic cells compared
to control cells. The percentage of apoptotic cells in
the HATi II 10 μM group was 11% ± 2.2% at 24 h
and 22.8% ± 1.7% at 48 h, the percentage of apoptotic
cells in the HATi II 20 μM group was 18.7% ± 0.8%
at 24 h and 34.9% ± 3.3% at 48 h, compared to 3.6% ±
1.02% at 24 h and 5.7% ± 0.56% at 48 h for control cells
(P < 0.01; Figure 2A and 2B). Cell cycle alterations were
Figure 4 (See legend on next page.)
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Figure 4 Microarray analysis of the expression profiles of HATi II-treated and DMSO-treated U251 cells. (A, B) The box plot is a
convenient way to quickly visualize the distributions of a dataset for mRNA (A) and lncRNA (B) profiles. The distributions of the log2 ratios
between the groups after normalization are presented. (C) Differentially expressed mRNAs and (D) differentially expressed lncRNAs were analyzed
using hierarchical clustering. Hierarchical clustering analysis arranges samples into groups based on their expression level, which allows us to
evaluate the relationships between samples. “Red” indicates high relative expression, and “green” indicates low relative expression (mRNA fold
changes ≥ 5 and lncRNA fold changes ≥ 3).
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pected, DNA fragmentation was observed and increased
in a time dependent manner. The number of apoptotic
cells in the HATi II 10 μM group was 11.89% ± 1.7% at
24 h and 22.64% ± 4.4% at 48 hours; similar results were
obtained for SHG44 cells treated with 7.5 or 15 μM
HATi II for 24 or 48 h (Figure 2D–F).
As shown in Figure 3A and 3B, apoptotic bodies were
clearly observed in U251 and SHG44 cells that had been
treated with HATi II for 48 h and then stained with
Hochest 33342. Additionally, the TUNEL assay showed
that HATi II markedly increased the number of apop-
totic cells relative to the respective control U251 and
SHG44 cells treated with DMSO (Figure 3C and 3D).
These results were consistent with the Annexin V assay
and cell cycle analysis, and confirmed that HATi II in-
duces apoptosis in U251 and SHG44 cells. We obtained
similar results in U87 and HS683 treated with HATi II
(Additional file 2: Figure S1).
HATi II induces caspase-dependent apoptosis in glioma cells
As we observed that HATi II induced apoptosis in glioma
cells, we examined the cleavage of PARP, caspase-9 and
caspase-3 by Western blotting. The expression of cleaved
caspase-3, caspase-9 and PARP increased markedly in
U251 cells treated with 10 or 20 μM HATi II for 48 h and
SHG44 cells treated with 7.5 or 15 μM HATi II for 48 h
(Figure 3E and 3F). Additionally, caspase-3 and PARP
underwent cleavage in a dose-dependent manner in U251
and SHG44 cells treated with HATi II. These results con-
firmed that HATi II induces apoptosis in glioma cells by
activating the caspase-dependent pathway. We obtained
similar results in U87 and HS683 cells treated with
HATi II (Additional file 3: Figure S2).
Microarray analysis of differentially expressed genes in
HATi II-treated U251 cells
The Arraystar_Human_LncRNA_8x60k v3.0 1 micro-
array was used to identify differentially expressed lncRNA/
mRNA in HATi II-treated U251 cells for 48 h compared to
DMSO-treated control cells. The threshold of volcano plot
filtering used to screen the differentially expressed mRNAs
was a fold change > 2.0. In the lncRNA/mRNA expression
profiling data, we identified a total of 23773 mRNAs and
1949 differently expressed mRNAs in HATi II-treatedU251 cells (Figure 4A, Additional file 4: Table S2 and
Additional file 5: Table S3). Compared to DMSO-treated
control cells, 965 mRNAs were significantly upregulated
and 984 mRNAs were significantly downregulated in
HATi II-treated U251 cells. Clustering analysis was used
to visualize the relationships between the mRNA expres-
sion patterns present in the samples (fold changes ≥ 5;
Figure 4B).
In the lncRNA expression profiling data, we found a total
of 33327 long non-coding RNAs (lncRNAs) expressed in
U251 cells, of which 3492 were differently expressed in
HATi II-treated cells (Figure 4C, Additional file 6: Table S4
and Additional file 7: Table S5). Hierarchical clustering
analysis of the differently expressed lncRNAs with a fold
change ≥ 3-fold is presented in Figure 4D. A total of 743
lncRNAs close to coding genes were identified to be chan-
ged after HATi II treatment (Additional file 8: Table S6).
Gene ontology analysis of differentially expressed mRNA s
We performed ontologic pathway enrichment analysis
for the differently expressed genes and gene product en-
richment with particular attention to GO biological pro-
cesses and molecular function. Fisher’s exact test was used
to determine whether the overlap between the differen-
tially expressed gene list and the GO annotation list was
greater than that expected by chance (a P-value ≤ 0.05 is
recommended).
We found that the most enriched GOs targeted by the
upregulated and downregulated transcripts were involved
in a variety of functions including cellular processes, bio-
logical regulation, cell cycle, response to stimulus, immune
and defense response, signal transduction, transcriptional
regulation and metabolism (Figure 5A and 5B). The genes
associated with the most enriched GO terms in HATi II-
treated U251 cells were linked to DNA ligation, regulation
of protein processing, cell cycle and mitosis, and oxygen
transporter activity, and included HBMG2, CRCC4,TOP2A,
RAD51, A2M, C3, F12, KLKB1, GTSE1, CETN2, PLK4,
KLF11, KLF3B and HBM (Additional file 9: Table S7). In
contrast, the genes associated with the most enriched GO
terms in DMSO-treated U251 control cells included factors
involved in response to stimulus, immune system and
defense processes, and included S100A7, MMP3, BCL2,
HMOX1, APCS, IGF1, SP3, FOS, CXCL1, TIMP3, DUSP6,
MAPK10, CLEC7A and TLR8 (Additional file 10: Table S8).
Figure 5 (See legend on next page.)
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Figure 5 Bioinformatic analysis of the differentially expressed genes in HATi II-treated U251 cells. Gene ontology enrichment analysis
provides a controlled vocabulary to describe the attributes of differentially expressed transcripts in all organisms (p-values≤ 0.05 are
recommended). (A) Upregulated genes and (B) downregulated genes in HATi II-treated U251 cells. Pathway analysis is a functional analysis that
maps genes to KEGG pathways. The top five upregulated pathways (C) and top five downregulated pathways (D) in HATi II-treated U251 cells are
listed. The “p53 signaling pathway”, which is associated with apoptosis, was activated in HATi II-treated U251 cells. (E) Confirmation of the microarray
results. The expression of p53 signaling pathway-related genes in HATi II-treated U251, HS683, U87 and SHG44 cells was validated by quantitative
real-time PCR. The columns represent the log-transformed median fold changes in expression relative to DMSO-treated cells.
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The KEGG database was used to investigate the pathways
in which the differentially expressed genes are involved.
KEGG pathway annotations of the five most enriched
pathways are shown in Figure 5C and 5D. Specifically, the
upregulated pathways included alcoholism, p53 signaling
pathway, focal adhesion, propanoate metabolism, cell cyc-
ling, regulation of actin cytoskeleton and ECM-receptor
interactions. One of these pathways, the p53 signaling
pathway, contained 11 genes that were upregulated in
HATi II-treated cells.
To validate the results of the mRNA microarray assay,
quantitative RT-PCR analysis was performed to confirm
the expression of genes related to the p53 signaling path-
way in HATi II-treated U251, HS683, U87 and SHG44
cells and DMSO-treated control cells. Quantitative RT-
PCR demonstrated that CDK1, CCNG1, CCNE2, CCNB2,
Reprimo (RPRM), GTSE1 (B99), PTEN, SFN (stratifin),
RRM2, TP53I3 (PIG3) and P53AIP were upregulated by
HATi II (Figure 5E); these results were mostly consistent
with the results of microarray analysis.
Significant changes in the protein levels of factors
related to the p53 pathway were also observed in U251
cells treated with HATi II, as shown in Figure 6A and
6B. P53 and p21 were obviously upregulated by HATi II
treatment in a dose-dependent manner. A number of pro-
teins downstream of the p53 signaling pathway, such as
CDK1, CCNE2, Reprimo, PTEN, SFN and RRM2, were
also significantly increased in a dose-dependent manner in
U251 cells treated with HATi II, compared to control cells
(Figure 6B and 6C). These results indicate that HATi II
may activate p53 and promote transcription and activation
of genes downstream of the p53 pathway. As shown in
Figure 6A and 6B, Reprimo was significantly upregulated
by HATi II at both the mRNA and protein level. To deter-
mine the function of Reprimo in glioma cells treated with
HATi II, we knocked down the expression of Reprimo in
U251 cells using a siRNA. Silencing of reprimo attenuated
HATi II-induced cell death, (Figure 6E) and reduced the
number of apoptotic cells by almost 25% (Figure 6F).
Discussion
At present, the therapeutic options for glioma are insuffi-
cient, and more effective therapeutic options are urgentlyrequired; small-molecule inhibitors may represent specific,
less toxic candidate drugs. Recent research has indicated
that a variety of small-molecule inhibitors that target
HATs can induce growth arrest, inhibit proliferation, in-
duce apoptosis or affect differentiation in tumor cells
[16-18]. HATi II, a novel p300/CBP-selective HAT in-
hibitor reduced histone H3 acetylation and induced
chromatin condensation in HeLa cells. In this study, we
investigated the effects and mechanism of action of HATi
II in glioma cell lines.
In this study, we demonstrated that HATi II can inhibit
the growth of glioma cell lines, as well as neuroblastoma
and Wilms tumor cell lines (data not shown), which sug-
gests that HATi II exerts broad spectrum anti-cancer
activity. P300 is required for orderly G1/S cell cycle phase
transition in human cancer cells, and inhibition of p300
blocks progression into the S-phase of cell cycle [26,28].
The p300/CBP HAT inhibitor compound C646 has been
shown to inhibit the growth of both melanoma and non-
small-cell-lung (NSCL) cancer cell lines [22]. In our study,
the CKK-8 assay, Hoechst 33342 staining, the Annexin V
assay, flow cytometry and the TUNEL assay demonstrated
that HATi II inhibited proliferation and induced cell cycle
arrest and apoptosis in glioma cell lines. DNA fragmenta-
tion was observed after 24 h in HATi II-treated cells, and
increased in a time-dependent manner. In prostate cancer
cells, inhibition of p300 induced apoptosis via multiple
pathways, and also decreased the expression of MMP-2
and MMP-9, which reduced the migratory and invasive
ability of the cells [25].
Apoptosis is a genetically controlled mechanism of cell
death that is essential for the elimination of unwanted
cells during normal development and for the maintenance
of tissue homeostasis [29,30]. Classical caspase-dependent
apoptosis requires proteolytic activation of caspases that
are synthesized as latent proenzymes. Once activated,
caspases cleave a wide range of molecules, eventually re-
sulting in cellular destruction [31]. Cleavage of PARP by
caspases is considered to be a hallmark of apoptosis.
In our experiments, HATi II increased the expression
of cleaved PARP, caspase-9 and caspase-3 in U251 and
SHG44 cells. Cleavage of caspase-3 and PARP is indicative
of apoptosis and confirmed that HATi II induced apop-
tosis via the caspase-dependent pathway. This observation
Figure 6 (See legend on next page.)
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Figure 6 Protein expression of factors related to the p53 signaling pathway in U251 cells treated with HATi II. Western blot analysis of
p53 and p21 (A) and factors downstream of the p53 signaling pathway (B, C) in U251 cells treated with HATi II. (D) Western blot analysis
confirming siRNA-mediated knockdown of Reprimo. (E) The morphological assay indicated that knockdown of Reprimo markedly reduced cell
death in a dose-dependent manner in U251 cells treated with 10 or 20 μmol/l HATi II for 48 h. (F) The hoechst 33342 staining assay indicated that
knockdown of Reprimo reduced apoptosis in U259 cells treated with 10 μmol/l HATi II for 48 h compared with control cells; **P < 0.01.
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ity of NU9056, which is a histone acetyltransferase inhibi-
tor. NU9056 inhibits cell growth and induces apoptosis
via caspase activation in prostate cancer cell lines [32].
In addition, it is noteworthy that both cell cycle arrest
and apoptosis were observed in neuroblastoma cell lines
(IMR-32 and SH-SY5Y) treated with HATi II (data not
shown), which suggests that HATi II has potential for
use in the clinic.
Microarray analysis demonstrated that 965 mRNAs
were significantly upregulated and 984 mRNAs were sig-
nificantly downregulated (≥2.0-fold) in HATi II-treated
U251 cells. Additionally, 3492 lncRNAs were identified
to be differently expressed in HATi II-treated U251 cells.
In recent years, multiple studies have demonstrated that
nearly every step in the life cycle of a gene can be regu-
lated by lncRNAs [33]. Nevertheless, the role of lncRNAs
in apoptosis not well-studied. In this study, a total of
743 lncRNAs close to coding genes were identified to
changed in HATi II-treated cells. Serine/threonine kinase
40 (STK40), a negative regulator of NF-kappa-B and p53-
mediated gene transcription [34], is the coding gene
closest to lncRNA chr1:36804800-36856000+, which
was upregulated 10-fold after HATi II treatment. BCL2-
associated athanogene 6 (BAG6), the coding gene closest
to lncRNA NR_002812 that was upregulated 5–fold by
HATi II, is implicated in the regulation of apoptosis.
After DNA damage, BAG6 accumulates in the nucleus
and forms a complex with p300/EP300, enhancing p300/
EP300-mediated p53/TP53 acetylation leading to increased
p53/TP53 transcriptional activity [35,36]. In addition,
RASSF1 (Ras Association (RalGDS/AF-6) Domain Family
Member 1) is the coding gene closest to the downre-
gulated lncRNA BC033528, RASSF1 has been shown to
induce cell cycle arrest and is required for death receptor-
dependent apoptosis [37]. Therefore, these results indicate
that lncRNAs may play a role in HATi II-induced apop-
tosis in glioma cell lines.
GO analysis showed that the differentially expressed
mRNAs with known functions are involved in a variety
of processes including cellular processes, biological regula-
tion, cell cycle, response to stimulus, immune and defense
response, signal transduction, transcriptional regulation
and metabolism. Numerous signaling pathways and mole-
cules are involved in apoptosis [29,38]. One major apop-
totic signaling pathway involves the p53 tumor suppressor.KEGG pathway annotation demonstrated that the p53 sig-
naling pathway was activated by HATi II, which sug-
gested that HATi II may induce apoptosis in U251
cells via activation of the p53 signaling pathway.
Based on our analysis of this analysis, quantitative real-
time PCR was used to verify the expression of a number
of crucial target genes downstream of p53, to test the
hypothesis that HATi II induces p53 transcription-
dependent death and exclude the possibility of false posi-
tive results from the microarray.
A number of differently expressed genes were chosen
as markers of the transcriptional function of p53. CDK1,
CCNG1, CCNE2, CCNB2 and p53 are transcriptionally
regulated at different phases of the cell cycle. Reprimo
appears to induce cell cycle arrest by inhibiting CDK1
activity and nuclear translocation of the CDC2 cyclin B1
complex, and may be involved in regulation of p53-
dependent G2 cell cycle arrest. B99 is only expressed in
the S and G2 phases of the cell cycle, and in response
to DNA damage, it accumulates in the nucleus and
binds to p53, which shuttles it out of the nucleus and
represses its ability to induce apoptosis [39]. Tumor
protein p53-inducible protein 3 (TP53I3) is induced
by the tumor suppressor p53 and is thought to be involved
in p53-mediated cell death [40]. Quantitative real-time
PCR demonstrated that these p53-transcriptionally reg-
ulated molecules, including CDK1, CCNG1, CCNE2,
CCNB2, Reprimo, GTSE1, PTEN, SFN, TP53I3 and DDB2
were upregulated by HATi II in U251 cells, in confirm-
ation of the results of the microarray. Significant dose-
dependent increases in the protein levels of p53 and p21
were also observed subsequent to treatment with HATi II.
Other proteins downstream of the p53 signaling pathway,
such as CDK1, CCNE2, Reprimo, PTEN, SFN and RRM2,
were also significantly and dose-dependently upregulated
by HATi II.
The p53 pathway has been reported to be involved in
a large number of biological processes, including acetyl-
ation. P53 was the first non-histone protein shown to be
acetylated by HATs, and p53 acetylation is mediated by
the p300 and CBP acetyltransferases in vivo [41]. Thus, we
suggest that inhibition of HATs may lead to deacetylation
of p53 and result in transactivation of the p53-regulated
genes that regulate apoptosis. However, additional research
is required to explore the precise mechanism by which
HATi II affects the p53 pathway.
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HATi II inhibits proliferation and induces apoptosis via
the caspase-dependent pathway in glioma cell lines, pos-
sibly by activating the p53 signaling pathway. This study
provides a basis for further investigation of the molecular
mechanism by which HATi II induces apoptosis and indi-
cates that HATi II may have potential as a therapeutic
option for human glioma.
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